Fibrodysplasia Ossificans Progressiva (FOP) Information
Synopsis: Fibrodysplasia ossificans progressiva (FOP) is where muscle and connective tissues are slowly replaced by bone referred to as ossification. The malformation of the person's toes is a characteristic sign of FOP and is often the first sign of the disorder. While the sign is significant, it may not be recognized due to the rarity of the disease. FOP is, fortunately, a sporadic form of disorder; it is believed to occur in around one out of every two million people in the world.
- Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia ossificans progressiva (FOP) is a disorder where a person's muscle and connective tissues, such as ligaments and tendons, are slowly replaced by bone through a process referred to as 'ossification,' forming bone outside of their skeleton, constraining their ability to move. The ossification process usually becomes noticeable during early childhood, beginning with the person's shoulders and neck and proceeding down their body into their limbs. The formation of extraskeletal bone causes a progressive loss of mobility as the person's joints become affected.
Persons affected by FOP experience an inability to fully open their mouths, potentially causing eating and speaking difficulties. As time passes, they can also experience malnutrition due to problems with eating, as well as breathing difficulties due to the formation of extra bone around their rib cage, which restricts the expansion capabilities of their lungs. Any form of trauma to the muscles of persons with FOP, such as invasive medical procedures or a fall, might trigger episodes of inflammation and swelling, referred to as 'myositis,' that is followed by an increase in ossification in the area of the person's body that has been injured. Persons with FOP can also experience flare-ups from viral illnesses like the flu. One of the signs associated with FOP is a malformation of the person's big toes. The abnormality of the person's big toes is a characteristic feature that assists in distinguishing the disorder from other muscle and bone problems. Persons affected by FOP may also have short thumbs or additional skeletal abnormalities.
The U.S. Social Security Administration (SSA) has included Fibrodysplasia Ossificans Progressiva as a Compassionate Allowance to expedite a disability claim.
Causes of FOP
FOP is, fortunately, a sporadic disorder; it is believed to occur in around one out of every two million people worldwide. Mutations in the ACVR1 gene cause fibrodysplasia ossificans progressiva (FOP). The ACVR1 gene provides instructions for producing a protein family member called 'bone morphogenetic protein type I (BMP)' receptors. The ACVR1 protein is found in several tissues in a person's body, including cartilage and skeletal muscle. The protein assists in controlling the development and growth of a person's muscles and bones, including the gradual replacement of cartilage by bone or 'ossification,' which happens in average skeletal maturation as a person ages from birth to young adulthood.
Medical researchers believe a mutation in the ACVR1 gene might change the receptor's shape in certain conditions, disrupting mechanisms that control the receptor's activity. Due to this process, the receptor might remain in a consistent, 'on,' state. Remaining in such a state causes overgrowth of the person's bone and cartilage, a fusion of their joints, and results in the signs and symptoms of fibrodysplasia ossificans progressiva (FOP).
Symptoms of FOP
FOP often starts in the person's shoulders and neck, progressing along their back, trunk, and limbs. Malformation of the person's toes, which present as short, bent, and at times curved inward, is always a characteristic of FOP and is observable at the time of the person's birth. The malformation of the person's toes causes few problems, although they are an early sign of FOP before the onset of ossification. While FOP is congenital, meaning it begins before the person's birth, the ossification process does not begin before birth.
Most people affected by FOP learn they have the disorder before they reach the age of ten. Inflammation and sometimes painful swelling, commonly in their back and shoulder areas and at times involving their head or scalp, are usually initial signs of FOP. The swelling associated with FOP eventually clears up, although it leaves behind a new mature bone formation.
Individuals with FOP experience various rates of new bone formation. Some people experience rapid bone progression, while others experience a more gradual progression of bone formation. The rate of progression cannot be predicted, although there seems to be a pattern to the progression. People with the disorder can experience bone formation in their shoulders, neck, and upper back early in life and in their knees and hips during their teenage years or early adulthood, for example.
The malformation of the person's toes is a characteristic sign of FOP and is often the first sign of the disorder. While the sign is significant, it may not be recognized due to the rarity of the disorder. A conclusive diagnosis of FOP cannot be made based on the presence of toe malformation alone. A conclusive diagnosis of FOP depends on genetic testing and observation of additional symptoms the person is experiencing that are associated with the disorder. An X-ray will show additional bone, for example.
Swelling that appears as tumors on the person's neck and back usually appears before they reach the age of ten. If the person has experienced physical trauma, they might also present with additional bone in the affected area of their body. At first, the areas that have been affected can be red and painful, potentially hot to the touch; common symptoms of inflammation. Parents of children with FOP have also noted that their children experience fever in addition to these symptoms.
The fact that FOP is so rare finds several doctors incorrectly diagnosing children with the disorder. Diagnosing FOP can take months or even years because of its rarity and unfamiliarity on the part of doctors. Explanations that families are commonly provided with include fibromatosis and cancer. Misdiagnosis or delays in achieving a diagnosis can cause harm to those affected by FOP, leading to inappropriate testing such as biopsies that may cause flare-ups and permanent immobility, as well as other treatments that are inappropriate such as chemotherapy.
Treatment of FOP
Unfortunately, medical science has not discovered a proven, effective treatment for FOP. Increased understanding of the underlying cause of FOP leads to medication-based means for treating the disorder. The unpredictable nature of FOP often makes it hard to assess any therapeutic intervention because the disorder's symptoms come and go. Determining if any particular treatment has been successful or not is made more difficult because it is hard to tell if the person's flare-up has run its course.
The flare-ups people with FOP experience are unpredictable and sporadic; the rate at which the disease progresses in individuals is equally varied. Several studies on the natural history of FOP have shown that attempts to predict the duration, occurrence, or severity of an FOP flare-up are impossible. However, characteristic anatomic patterning has been described.
A short course of high-dose corticosteroids, started within twenty-four hours of a flare-up, might assist in reducing intense tissue edema and inflammation people with FOP experience during the early stages of the disease. The use of corticosteroids should be restricted to very early treatment of flare-up symptoms affecting the person's jaw, major joints, or submandibular area. Corticosteroids should not be used for the treatment of flare-ups involving the person's neck, back, or trunk because of the long duration and recurring nature of the flare-ups, as well as the difficulties with assessing the true onset of the flare-ups.
The dose of corticosteroids a doctor administers to a person with FOP depends on the person's body weight. The dose is usually administered as a single dose over no more than four days. The potential danger associated with flare-ups and FOP in a person's submandibular region may find a doctor administering corticosteroids for a slightly longer period and tapering the dose for the duration of the flare-up until the acute swelling has subsided. The corticosteroids are discontinued, and a non-steroidal anti-inflammatory drug (NSAID), or cox-2 inhibitor combined with a leukotriene inhibitor, might be prescribed for symptoms of the flare-up. A doctor may use mast cell inhibitors and amino-bisphosphonates as well.
FOP flare-ups, particularly around the knees and hips, can be extremely painful and might require a course of narcotic analgesia in combination with the use of NSAIDs, cox-2 inhibitors, and either oral or intravenous glucocorticoids. Other types of transient pain syndromes can be caused by neuropathies resulting from acute flare-ups, inflammation of osteochondromas, transient bursitis, muscle fatigue, or arthritis. People with FOP can experience metabolic changes to relatively healthy skeletal muscle, leading to muscle spasms and fiber shortening. Muscle relaxants such as cyclobenzaprine, Lioresal, or metaxalone can help to decrease muscle spasms and help the person to maintain their levels of activity.
Surgical attempts to remove heterotopic bone presents the risk of provoking painful and explosive new bone growth in persons with FOP. Biopsies of FOP lesions are never indicated because they can cause additional heterotopic ossification in the biopsied person. Falls on the part of persons with FOP may lead to serious injury and flare-ups as well.
People with FOP have a self-perpetuating fall cycle. Minor soft tissue trauma often exacerbates the disorder, resulting in ossification and joint ankylosis. The resulting mobility restriction from joint ankylosis impairs the person's balancing abilities, causing instability resulting in more falls, with the potential for head injuries, concussions, loss of consciousness, back and neck injuries, and more. Children with FOP should pursue less physically interactive play; it may be helpful. They should completely avoid high-risk circumstances; it can help them to avoid falls.
Palovarotene for Treatment of Fibrodysplasia Ossificans Progressiva
Clementia Pharmaceuticals, Inc. announced on 21 Nov. 2014 that the European Medicines Agency (EMA) had granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).
Palovarotene, an investigational retinoic acid receptor gamma agonist, is currently in Phase 2 clinical trial in patients with FOP and was previously designated an orphan drug by the U.S. Food and Drug Administration. Clementia recently announced the launch of a 12-month, open-label extension study for patients with FOP who complete the 12-week, randomized, double-blind, placebo-controlled study of palovarotene.
Thomas C. Weiss is a researcher and editor for Disabled World. Thomas attended college and university courses earning a Masters, Bachelors and two Associate degrees, as well as pursing Disability Studies. As a Nursing Assistant Thomas has assisted people from a variety of racial, religious, gender, class, and age groups by providing care for people with all forms of disabilities from Multiple Sclerosis to Parkinson's; para and quadriplegia to Spina Bifida.
Discover Related Topics ▶ Page Information, Citing and Disclaimer Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page. Permalink: <a href="https://www.disabled-world.com/disability/types/fop.php">Fibrodysplasia Ossificans Progressiva (FOP) Information</a> Cite This Page (APA): Thomas C. Weiss. (2010, March 30). Fibrodysplasia Ossificans Progressiva (FOP) Information. Disabled World. Retrieved December 4, 2023 from www.disabled-world.com/disability/types/fop.php
Share This Information To:
𝕏.com Facebook Reddit
Page Information, Citing and Disclaimer
Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.
Permalink: <a href="https://www.disabled-world.com/disability/types/fop.php">Fibrodysplasia Ossificans Progressiva (FOP) Information</a>
Cite This Page (APA): Thomas C. Weiss. (2010, March 30). Fibrodysplasia Ossificans Progressiva (FOP) Information. Disabled World. Retrieved December 4, 2023 from www.disabled-world.com/disability/types/fop.php
Disabled World provides general information only. Materials presented are never meant to substitute for qualified professional medical care. Any 3rd party offering or advertising does not constitute an endorsement.